Eosinophilia:
Bone Marrow Diagnostic Algorithm
Eosinophilia identified via routine evaluation.
Evaluate for secondary causes of eosinophilia.
Was a secondary cause found?
YES NO
Disease-specific workup Assess peripheral blood/bone
marrow (BM) morphology
Morphologic features of other Increased eosinophils
hematologic disease: eg, mastocytosis, and precursors only
myeloid neoplasm, lymphoma
Order*:
■ Immunohistochemistry (IHC) for tryptase, CD117, and CD25.
Disease-specific workup
■ KITVS / KIT Asp816Val Mutation Analysis, Varies
■ CHRBM / Chromosome Analysis, Hematologic Disorders, Bone Marrow
■ EOSMF / Chronic Eosinophilia, Specified FISH, Varies and specify the
CHIC2 probe set
■ EXHR / Hematologic Disorders, DNA and RNA Extract and Hold, Varies
■ T-Cell panel by flow cytometry
Consider: TCGBM / T-Cell Receptor Gene Rearrangement, PCR, Bone Marrow
Chromosome and fluorescence in Abnormal T-cell phenotype Abnormal CD25 positive
situ hybridization (FISH) results** and clonal T-cell receptor mast cells and KIT
gene rearrangement Asp816Val alteration
FISH-positive for FIP1L1::PDGFRA Other clonal myeloid No clonal Consider Mastocytosis workup
Abnormal chromosome analysis abnormality abnormality lymphocytic variant See Mast Cell Disorder:
and confirmatory FISH showing hypereosinophilic Diagnostic Algorithm,
rearrangement of: syndrome Bone Marrow
■ 4q12 (PDGFRA)
■ 5q32 (PDGFRB)
■ 8p11.23 (FGFR1)
■ 9p24.1 (JAK2)
■ 9q34 (ABL1)
Myeloid neoplasm with Consider chronic Consider the following diagnoses:***
■ PDGFRA rearrangement eosinophilic leukemia, ■ Reactive eosinophilia
■ PDGFRB rearrangement not otherwise specified ■ Idiopathic hypereosinophilia
■ FGFR1 rearrangement ■ Idiopathic hypereosinophilia syndrome
■ JAK2 rearrangement
■ FLT3 rearrangement
■ ETV6::ABL1 rearrangement
*Do not routinely order the following: BCR::ABL FISH or PCR, FISH for PDGFRB or FGFR1, mast cell flow cytometry
**Detection of the t(5;14)(q31;q32) [IGH::IL3] mutation is associated with B-lymphoblastic leukemia with reactive eosinophilia.
***If there is significant dysplasia (hypercellularity, odd megakaryocytes, ring sideroblasts, etc.), or if the clinical scenario is
worrisome for a clonal myeloid process, consider adding next-generation sequencing and FISH for PDGFRB, FGFR1,
ABL1, and JAK2, as rarely these may be cryptic.
© Mayo Foundation for Medical Education and Research (MFMER). All rights reserved. 06/2024